New hope for rare, aggressive breast cancer: drug combo shows promise before surgery
NCT ID NCT02623972
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tested a drug called eribulin combined with standard chemotherapy given before surgery for a rare and aggressive type of breast cancer called HER2-negative inflammatory breast cancer. The goal was to see if this approach could eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. The study enrolled 22 adults with this specific cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.